Cencora director awarded 905 shares in stock grant

DURCAN DERMOT MARK reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/09/2026 - 04:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DURCAN DERMOT MARK reported acquisition or exercise transactions in this Form 4 filing.

Cencora, Inc. director Dermot Mark Durcan reported an award of 905 shares of common stock on March 5, 2026, valued at $359.28 per share. The grant was in the form of restricted stock units received for no cash consideration and will vest 100% on the first anniversary of the grant date. Following this award, Durcan directly holds 23,767 shares of Cencora common stock.

Insider Trade Summary

Grant/Award: 905 shares

Grant/Award 1 txn

Insider DURCAN DERMOT MARK

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	905	$359.28	$325K

Holdings After Transaction: Common Stock — 23,767 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cencora (COR) director Dermot Mark Durcan report?

Cencora director Dermot Mark Durcan reported an award of 905 shares of common stock. The shares were granted as restricted stock units at $359.28 per share and will vest fully one year after the grant date, increasing his direct holdings to 23,767 shares.

Was the Cencora (COR) Form 4 transaction a market purchase or a stock award?

The Form 4 transaction was a stock award, not a market purchase. Durcan received 905 restricted stock units for no cash consideration, with all units scheduled to vest on the first anniversary of the March 5, 2026 grant date.

How many Cencora (COR) shares does Dermot Mark Durcan own after this Form 4?

After the reported award, Dermot Mark Durcan directly owns 23,767 shares of Cencora common stock. This total reflects the addition of 905 restricted stock units granted on March 5, 2026, which vest 100% one year after the grant date.

What are the vesting terms of the Cencora (COR) restricted stock units granted to Durcan?

The restricted stock units granted to Durcan vest 100% on the first anniversary of the grant date. He received 905 units for no cash consideration, and once vested, they convert into shares of Cencora common stock based on the award terms.

At what price were the Cencora (COR) restricted stock units to Dermot Mark Durcan valued?

The 905 restricted stock units granted to Durcan were valued at $359.28 per share. This price is used for reporting purposes on the Form 4 and reflects the per-share value assigned to the award on the March 5, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DURCAN DERMOT MARK

(Last) (First) (Middle)

1 WEST FIRST AVENUE

(Street)

CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cencora, Inc. [ COR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		905	A	$359.28	23,767(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant.

Remarks:

	/s/ Elizabeth S. Campbell, attorney-in-fact for D. Mark Durcan	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.